Price
CHART BY
Frequently asked questions
What is ADMA Biologics's market capitalization?
The market capitalization of ADMA Biologics is $2.31B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is ADMA Biologics's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for ADMA Biologics is 16.17. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for ADMA Biologics?
ADMA Biologics's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.599. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for ADMA Biologics's stock?
Currently, 2 analysts cover ADMA Biologics's stock, with a consensus target price of $24.00. Analyst ratings provide insights into the stock's expected performance.
What is ADMA Biologics's revenue over the trailing twelve months?
Over the trailing twelve months, ADMA Biologics reported a revenue of $510.17M.
What is the EBITDA for ADMA Biologics?
ADMA Biologics's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $199.54M. EBITDA measures the company's overall financial performance.
What is the free cash flow of ADMA Biologics?
ADMA Biologics has a free cash flow of $27.82M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does ADMA Biologics have, and what sector and industry does it belong to?
ADMA Biologics employs approximately 647 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of ADMA Biologics's shares?
The free float of ADMA Biologics is 229.62M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $2.31B
- EPS (TTM)
- $0.599
- Free Float
- 229.62M
- P/E ratio (TTM)
- 16.17
- Revenue (TTM)
- $510.17M
- EBITDA (TTM)
- $199.54M
- Free Cashflow (TTM)
- $27.82M
Pricing
- 52W span
- $7.22$25.67
Analyst Ratings
The price target is $24.00 and the stock is covered by 2 analysts.
Buy
1
Hold
1
Sell
0
Information
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.
- Employees
- 647
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- ADMA
Fundamentals & EOD data from FactSet